Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04059445
Other study ID # FURC-II-REGEN
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date October 15, 2019
Est. completion date November 27, 2023

Study information

Verified date November 2023
Source University of Oslo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Teeth with furcation grade II defects will be treated with open flap debridement and regenerative therapy with biphasic calcium phosphate combined with either enamel matrix proteins or a collagen membrane.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date November 27, 2023
Est. primary completion date November 27, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Subject must be = 20 years - Subject must have periodontal disease as determined by the World Workshop 2017 criteria - Subjects must be undergoing periodontal treatment or follow-up and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade II with PPD >4 mm, and the furcation fornix must be below a tangential line from the distal to mesial interproximal crestal bone level - Competent to give consent Exclusion Criteria: The following must not be present at the time of enrolment; - Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment - Present or past use of bisphosphonate treatment - Pregnant or nursing subjects - Patients classified as > class 2 according to the ASA (American Society of Anesthesiologists) physical status classification - Previous surgical therapy of included furcation defects - Inability to comprehend and respond to the quality of life questionnaire - Dental restorations or prosthesis involving the furcation area - Root fractures or suspected infractions - Caries lesions in the furcation area - No systemic antibiotic treatment within 3 months prior to intervention

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Regenerative therapy with biphasic calcium phosphate + collagen membrane.
Drug:
Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.

Locations

Country Name City State
Norway Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo Oslo

Sponsors (1)

Lead Sponsor Collaborator
University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of furcation grade level Proportion of sites demonstrating improvement in furcation grade level as measured with Nabers probe 12 months after treatment
Primary Change of furcation grade level Proportion of sites demonstrating improvement in furcation grade level as measured with Nabers probe 24 months after treatment
Secondary Changes in patient-reported quality of life (QoL) To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected, (2) less than once a month, (3) once or twice a month, (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome.
Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected, including category (1).
Preoperatively compared to 24 months after treatment
Secondary Changes in patient-reported quality of life (QoL) To assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of "The Oral Impacts on Daily Performance (OIDP)" instrument. Each question is assessed by a 5-point scale; (1) never affected, (2) less than once a month, (3) once or twice a month, (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome.
Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected, including category (1).
Preoperatively compared to 12 months after treatment
Secondary Changes in defect morphology assessed by CBCT Cone beam computed tomography will be acquired at baseline, 2 weeks postoperatively and 24 months postoperatively. This outcome measures quantitative morphologic changes in the furcation defects at 24 months 24 months after treatment
Secondary Changes in CAL Changes in clinical attachment level will be measured with a probe in mm 12 months after treatment
Secondary Changes in CAL Changes in clinical attachment level will be measured with a probe in mm 24 months after treatment
Secondary Changes in PPD Changes in pocket probing depth will be measured with a probe in mm 12 months after treatment
Secondary Changes in PPD Changes in pocket probing depth will be measured with a probe in mm 24 months after treatment
Secondary Radiographic changes Standardized intraoral bitewing radiographs will be obtained and compared to baseline radiographs 12 months after treatment
Secondary Radiographic changes Standardized intraoral bitewing radiographs will be obtained and compared to baseline radiographs 24 months after treatment
Secondary Pain following surgery Pain sensation for one week posteoperatively will be recorded on a visual analog scale scale from 0-10. 0 is equivalent to no pain, whereas 10 is the highest pain imagineable. Daily for 1 week postoperatively
Secondary Caries assessment Caries in furcation defect assessed with an explorer will be recorded as (Y/N) 12 months
Secondary Caries assessment Caries in furcation defect assessed with an explorer will be recorded as (Y/N) 24 months
See also
  Status Clinical Trial Phase
Completed NCT04712630 - Non-Incised Papillae Surgical Approach (NIPSA) With and Without Graft N/A
Recruiting NCT03997552 - NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration N/A
Completed NCT04478864 - Knowledge, Practice and State of Periodontal Health
Completed NCT03507868 - YKL-40 and IL-6 Levels in Periodontal Disease
Completed NCT05720481 - Impact of Periodontal Treatment on Growth Differentiation Factor-15 Levels N/A
Recruiting NCT06052150 - Oral Health In Cirrhosis of the Liver (ORACLE)
Recruiting NCT06025955 - Evaluation of Outcomes of Minimally Invasive Non- Surgical Versus Surgical Therapy in Furcation Involvement. N/A
Recruiting NCT03510702 - SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
Completed NCT05631600 - Manuka Honey as an Adjunct to Non-surgical Periodontal Therapy: Clinical Study Phase 2/Phase 3
Active, not recruiting NCT05068778 - Development of an AI App to Improve Compliance in Periodontal Maintenance Patients
Not yet recruiting NCT05178563 - Mechanisms of Acute Inflammation Following Periodontal Treatment N/A
Recruiting NCT06086821 - Clinical Relevance of Different Time of Periodontal Re-evaluation N/A
Recruiting NCT06224699 - Toothpaste With Sodium Carbonate in Patients With Gingivitis N/A
Not yet recruiting NCT05721313 - Vital Root Amputation in Molars With Advanced Periodontal Furcation Involvement: a Preliminary Study N/A
Completed NCT06306937 - Serum Levels of Vitamin D and IL8 in Patients With Periodontitis
Completed NCT06040944 - Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
Recruiting NCT04669717 - Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies Phase 4
Completed NCT05576142 - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma
Completed NCT04017078 - Assessment of Carotid Artery Calcifications
Not yet recruiting NCT03588507 - Clinical and Radiographic Evaluation of PPF With or Without NCHA Bone in Treatment of Intrabony Defects N/A